EDX Medical Group Plc Director Dealing

 
TIDMEDX 
 
This announcement contains inside information as stipulated under the UK 
version of the Market Abuse Regulation No 596/2014 which is part of English law 
by virtue of the European (Withdrawal) Act 2018, as amended.  On publication of 
this announcement via a regulatory information service, this information is 
considered to be in the public domain and such persons shall therefore cease to 
be in possession of inside information. 
 
                         LONDON: March 13 March, 2023 
 
                             EDX Medical Group Plc 
 
                               Director Dealing 
 
EDX Medical Group plc ("EDX Medical" or the "Company"), which develops 
innovative digital diagnostic products and services for cancer, heart disease, 
neurology and infectious disease testing, today announces that Jason Holt, 
Non-executive Chairman of the Company, purchased 400,000 ordinary shares in the 
Company at an aggregate price of 3.025 pence per ordinary share on 10 March 
2023. Following this purchase, Jason Holt owns 4,400,000 ordinary shares, 
representing 1.74% of the issued share capital. 
 
The directors of the Company accept responsibility for the contents of this 
announcement. 
 
For more information, please contact: 
 
EDX Medical PLC 
 
Mike Hudson 
 
Tel: [phone] 
 
Peterhouse: 
 
Guy Miller 
 
Tel: [phone] 
 
Media House International, 
 
Ramsay Smith 
 
Tel:  [phone]: 
 
email: [e-mail] 
 
Notification and public disclosure of transactions by persons discharging 
managerial responsibilities and persons closely associated with them. 
 
1  Details of the person discharging managerial responsibilities / person 
   closely associated 
 
a) Name                          Jason Holt 
 
2  Reason for the notification 
 
a) Position/status               Non-executive Chairman 
 
b) Initial notification /        Initial notification 
   Amendment 
 
3  Details of the issuer, emission allowance market participant, auction 
   platform, auctioneer or auction monitor 
 
a) Name                            EDX Medical Group Plc 
 
b) LEI                           213800BZVJZTMCZ6DJ63 
 
4  Details of the transaction(s): section to be repeated for (i) each type of 
   instrument; (ii) each type of transaction; (iii) each date; and (iv) each 
   place where transactions have been conducted 
 
a) Description of the financial  Ordinary shares of 1 pence each in EDX 
   instrument, type of           Medical Group Plc 
   instrument 
   Identification code           Identification code (ISIN) for EDX Medical 
                                 Group Plc ordinary shares: GB00BNDMJS47 
 
b) Nature of the transaction     Purchase of Ordinary Shares 
 
c) Price(s) and volume(s)         Price(s)    Volume(s) 
 
                                 3.025p       400,000 ordinary shares 
 
d) Aggregated information        N/A 
   - Aggregated volume 
   - Price 
 
e) Date of the transaction       10 March 2023 
 
f) Place of the transaction      AQSE Growth Market 
 
Notes for Editors: 
 
About EDX Medical Group 
 
EDX Medical develops and delivers innovative digital diagnostic products and 
services for cancer, heart disease, neurology and infectious disease testing, 
helping to predict disease risk, inform clinical decision-making and accelerate 
the development of new medicines. The company is listed on the Access Segment 
of the AQSE Growth Market (TIDM: EDX). 
 
EDX Medical was founded by Professor Sir Christopher Evans, OBE, a medical and 
life sciences entrepreneur with more than 30 years of experience in the sector, 
specialising in cancer treatments and diagnostics. 
 
By translating clinical insights into pragmatic solutions combining advanced 
biological and digital technologies, EDX Medical seeks to cost-effectively 
improve the detection of disease risk and personalise disease management in a 
timely fashion. Early disease detection and risk prediction is the most 
impactful way of reducing deaths and lowering the future costs of healthcare 
provision globally. 
 
EDX Medical operates a molecular biology and diagnostics laboratory in 
Cambridge, UK, from which it performs research & development (R&D), provides 
testing and genomic sequencing services, undertakes quality assurance and has 
established expertise in the design, development, validation and sourcing of 
diagnostic testing solutions. Key tests performed in this laboratory have been 
audited by the United Kingdom Accreditation Service (UKAS) and accredited to 
ISO 15189. 
 
www.edxmedical.co.uk 
 
https://www.toraxbiosciences.co.uk/ 
 
 
 
END 
 
 

(END) Dow Jones Newswires

March 13, 2023 03:00 ET (07:00 GMT)